🔴 Problem Identified
European venture capital has shifted from backing high-risk, innovative startups to focusing on safer, predictable returns with established business models. This "Safe Bet Syndrome" favors revenue traction and proven teams over breakthrough technologies and visionary founders, leading to smaller investments and higher valuations. Genuine innovation struggles to find patient, risk-tolerant funding, creating a gap between academic breakthroughs and commercial applications.
💡 Proposed Solution
Create an investment platform that aggregates long-term, risk-tolerant capital from family offices, sovereign wealth funds, and institutional investors, targeting early-stage deep tech and scientific breakthroughs. The platform offers a 15-20 year fund lifetime, co-investment opportunities, and expert commercialization support for transformative technologies, acting as both a fund and syndication network matching visionary founders with patient investors including educational content and due dil...
Register to read the full solution →
Market Size
Medium
Difficulty
High
Time to MVP
6+ months
Investment
High
Unlock Full Analysis
Get competitor analysis, cost breakdowns, implementation roadmaps, and AI-powered next steps.
Create Free AccountAlready have an account? Log in
Quick Overview
Target Audience
University spinouts, deep tech startups, family offices, sovereign funds, forward-thinking institutions
Revenue Potential
€5M - €30M range
Competition
Low
Key Advantage
Unique fund-life structure, deep partnerships with universities, specialized commercialisation support, ability to syndi...